The invention discloses a substituted pyrazole compound of formula (I), preparation method therefor, a pharmaceutical composition and a medical use thereof. The said compound features excellent stability, solubility, and low cytotoxicity, which is significantly beneficial for neurological protection, effectively preventing and treating nerve cell injuries. It is an ideal pharmaceutical compound for preventing or treating stroke, cerebral embolism, stroke sequelae, stroke-related motor dysfunction, mitochondrial encephalomyopathy, and amyotrophic lateral sclerosis. ##STR00001##

A photosensitive layer of an electrophotographic photosensitive member is a single layer and contains a charge generating material, a hole transport material, a first electron transport material, a second electron transport material, and a binder resin. The binder resin includes a polyarylate resin. The polyarylate resin includes repeating units (1), (2), (3), and (4).

##STR00001##

A percentage of the number of repeats of the repeating unit (3) relative to the total of the number of repeats of the repeating units (1) and the number of repeats of the repeating unit (3) is greater than 0% and less than 20%. The first electron transport material includes a compound represented by formula (A15) or (A16).

##STR00002##

The second electron transport material includes a compound represented by formula (B10), (B11), (B12), (B13), or (B14)

##STR00003##

A photosensitive layer of an electrophotographic photosensitive member is a single layer and contains a charge generating material, a hole transport material, a first electron transport material, a second electron transport material, and a binder resin. The binder resin includes a polyarylate resin. The polyarylate resin includes repeating units (1), (2), (3), and (4).

##STR00001##

A percentage of the number of repeats of the repeating unit (3) relative to the total of the number of repeats of the repeating units (1) and the number of repeats of the repeating unit (3) is greater than 0% and less than 20%. The first electron transport material includes a compound represented by formula (A15) or (A16).

##STR00002##

The second electron transport material includes a compound represented by formula (B10), (B11), (B12), (B13), or (B14)

##STR00003##

The invention discloses a substituted pyrazole compound of formula (I), preparation method therefor, a pharmaceutical composition and a medical use thereof. The said compound features excellent stability, solubility, and low cytotoxicity, which is significantly beneficial for neurological protection, effectively preventing and treating nerve cell injuries. It is an ideal pharmaceutical compound for preventing or treating stroke, cerebral embolism, stroke sequelae, stroke-related motor dysfunction, mitochondrial encephalomyopathy, and amyotrophic lateral sclerosis.

##STR00001##

The present invention provides compounds of Formula (I):

##STR00001##

or stereoisomers, tautomers, or pharmaceutically-acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective ROCK inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating cardiovascular, smooth muscle, oncologic, neuropathologic, autoimmune, fibrotic, and/or inflammatory disorders using the same.

A pharmaceutical preparation comprising ⊖A2-73 substantially free of A2-73. This invention further includes a method treating Alzeheimer's disease in a subject in need of such treatment by the method of administering a therapeutically effective amount of ⊖A2-73 substantially free of A2-73.

This invention yet further includes a method of classifying cells as to sigma receptor type by the method of exposing said cells to a detectable amount of ⊖A2-73 substantially free of A2-73 and determining the level of sigma receptor binding.

A pharmaceutical preparation comprising ⊖A2-73 substantially free of A2-73. This invention further includes a method treating Alzeheimer's disease in a subject in need of such treatment by the method of administering a therapeutically effective amount of ⊖A2-73 substantially free of A2-73.

This invention yet further includes a method of classifying cells as to sigma receptor type by the method of exposing said cells to a detectable amount of ⊖A2-73 substantially free of A2-73 and determining the level of sigma receptor binding.

The present invention relates to novel ACSS2 inhibitors having activity as anti-cancer therapy, treatment of alcoholism, and viral infection (e.g., CMV), composition and methods of preparation thereof, and uses thereof for treating viral infection, alcoholism, alcoholic steatohepatitis (ASH), non-alcoholic steatohepatitis (NASH), obesity/weight gain, anxiety, depression, post-traumatic stress disorder, inflammatory/autoimmune conditions and cancer, including metastatic cancer, advanced cancer, and dmg resistant cancer of various types.

The present invention relates to novel ACSS2 inhibitors having activity as anti-cancer therapy, treatment of alcoholism, and viral infection (e.g., CMV), composition and methods of preparation thereof, and uses thereof for treating viral infection, alcoholism, alcoholic steatohepatitis (ASH), non-alcoholic steatohepatitis (NASH), obesity/weight gain, anxiety, depression, post-traumatic stress disorder, inflammatory/autoimmune conditions and cancer, including metastatic cancer, advanced cancer, and dmg resistant cancer of various types.

The present invention relates to novel herbicidally active, substituted 1,5-diphenylpyrazolyl-3-oxyalkyl acids and 1-phenyl-5-thienylpyrazolyl-3-oxyalkyl acids and derivatives thereof according to the general formula (I) or agrochemically acceptable salts thereof, to processes for preparation thereof and to the use thereof for control of broadleaved weeds and weed grasses in crops of useful plants and for general control of broadleaved weeds and weed grasses in areas of the environment where plant growth is troublesome. The derivatives of the 1,5-diphenylpyrazolyl-3-oxyalkyl acids and 1-phenyl-5-thienylpyrazolyl-3-oxyalkyl acids especially include the esters, salts and amides thereof.